| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $58M |
Buys | $5,810,750 | 15 | 83 |
Sells | $26,020 | 3 | 17 |
| Leonard Braden Michael | 10 percent owner | 15 | $5.81M | 0 | $0 | $5.81M |
| Seyedkazemi Setareh | CHIEF DEVELOPMENT OFFICER | 0 | $0 | 1 | $1,848 | $-1,848 |
| Soparkar Peter | CHIEF OPERATING OFFICER | 0 | $0 | 1 | $5,920 | $-5,920 |
| Fischer Laurent | CEO, PRESIDENT AND DIRECTOR | 0 | $0 | 1 | $18,252 | $-18,252 |
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Over the last 12 months, insiders at Adverum Biotechnologies, Inc. have bought $5.81M and sold $26,020 worth of Adverum Biotechnologies, Inc. stock.
On average, over the past 5 years, insiders at Adverum Biotechnologies, Inc. have bought $1.82M and sold $377,640 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Leonard Braden Michael (10 percent owner) — $5.81M.
The last purchase of 50,000 shares for transaction amount of $148,950 was made by Leonard Braden Michael (10 percent owner) on 2025‑04‑23.
| 2025-05-15 | Sale | Fischer Laurent | CEO, PRESIDENT AND DIRECTOR | 9,126 0.0426% | $2.00 | $18,252 | +14.97% | |
| 2025-05-15 | Sale | Soparkar Peter | CHIEF OPERATING OFFICER | 2,960 0.0138% | $2.00 | $5,920 | +14.97% | |
| 2025-05-15 | Sale | Seyedkazemi Setareh | CHIEF DEVELOPMENT OFFICER | 924 0.0043% | $2.00 | $1,848 | +14.97% | |
| 2025-04-23 | Leonard Braden Michael | 10 percent owner | 50,000 0.2502% | $2.98 | $148,950 | -2.95% | ||
| 2025-04-22 | Leonard Braden Michael | 10 percent owner | 300,000 1.1918% | $3.00 | $900,000 | -4.39% | ||
| 2025-04-02 | Leonard Braden Michael | 10 percent owner | 15,209 0.0693% | $4.04 | $61,408 | -30.28% | ||
| 2025-03-31 | Leonard Braden Michael | 10 percent owner | 19,566 0.0942% | $4.38 | $85,668 | -31.12% | ||
| 2025-03-27 | Leonard Braden Michael | 10 percent owner | 16,593 0.0834% | $5.19 | $86,089 | -37.95% | ||
| 2025-03-26 | Leonard Braden Michael | 10 percent owner | 20,407 0.0981% | $5.04 | $102,841 | -38.19% | ||
| 2025-03-20 | Leonard Braden Michael | 10 percent owner | 30,600 0.1474% | $5.61 | $171,767 | -42.32% | ||
| 2025-03-19 | Leonard Braden Michael | 10 percent owner | 25,000 0.1096% | $4.94 | $123,390 | -39.83% | ||
| 2025-03-18 | Leonard Braden Michael | 10 percent owner | 62,341 0.2869% | $4.69 | $292,418 | -33.06% | ||
| 2025-02-28 | Leonard Braden Michael | 10 percent owner | 85,068 0.4042% | $4.60 | $391,015 | -27.18% | ||
| 2025-02-27 | Leonard Braden Michael | 10 percent owner | 86,802 0.4186% | $4.46 | $387,094 | -22.05% | ||
| 2025-02-26 | Leonard Braden Michael | 10 percent owner | 164,886 0.8826% | $4.01 | $660,979 | -17.94% | ||
| 2024-07-30 | Leonard Braden Michael | 10 percent owner | 85,800 0.3983% | $7.15 | $613,470 | -32.08% | ||
| 2024-07-18 | Leonard Braden Michael | 10 percent owner | 80,718 0.3739% | $9.11 | $735,737 | -43.35% | ||
| 2024-07-17 | Leonard Braden Michael | 10 percent owner | 135,546 0.5761% | $7.75 | $1.05M | -38.67% | ||
| 2024-02-07 | Lupher, Jr. Mark L. | director | 130,000 0.1654% | $1.35 | $175,500 | -73.31% | ||
| 2024-02-07 | Scopa James Paul | director | 100,000 0.1273% | $1.35 | $135,000 | -73.31% |
| Leonard Braden Michael | 10 percent owner | 191800 0.9181% | $423,878.00 | 15 | 0 | |
| Fischer Laurent | CEO, PRESIDENT AND DIRECTOR | 87488 0.4188% | $193,348.48 | 6 | 2 | <0.0001% |
| Soparkar Peter | CHIEF OPERATING OFFICER | 39154 0.1874% | $86,530.34 | 3 | 2 | <0.0001% |
| Seyedkazemi Setareh | CHIEF DEVELOPMENT OFFICER | 13768 0.0659% | $30,427.28 | 1 | 2 | +0.48% |
| Zygtech, LLC | 10 percent owner | 2438176 11.6711% | $5.39M | 0 | 3 | |
| Venrock Associates VI, L.P. | 10 percent owner | 2365471 11.3231% | $5.23M | 1 | 0 | |
| Venrock Healthcare Capital Partners II, L.P. | 10 percent owner | 2365471 11.3231% | $5.23M | 1 | 0 | |
| REGENERON PHARMACEUTICALS INC | 10 percent owner | 1809098 8.6598% | $4M | 1 | 0 | |
| Flynn James E | 10 percent owner | 654285 3.1319% | $1.45M | 1 | 0 | |
| Blumenkranz Mark S. | director | 522989 2.5035% | $1.16M | 0 | 13 | |
| Schwartz Steven Daniel | director | 367931 1.7612% | $813,127.51 | 0 | 7 | |
| Gasmi Mehdi | director | 274442 1.3137% | $606,516.82 | 0 | 22 | |
| Chalberg Thomas W. | Chief Executive Officer | 258988 1.2397% | $572,363.48 | 0 | 3 | |
| Clark Julie | Chief Medical Officer | 164723 0.7885% | $364,037.83 | 0 | 1 | |
| Lupher, Jr. Mark L. | director | 130000 0.6223% | $287,300.00 | 1 | 0 | <0.0001% |
| Riley Brigit | Chief Scientific Officer | 117435 0.5621% | $259,531.35 | 0 | 1 | |
| Rubinstein Linda M | Chief Financial Officer | 100000 0.4787% | $221,000.00 | 1 | 0 | <0.0001% |
| Scopa James Paul | director | 100000 0.4787% | $221,000.00 | 3 | 1 | <0.0001% |
| PATTERSON LEONE D | President and CFO | 97955 0.4689% | $216,480.55 | 0 | 6 | |
| Machado Patrick | director | 88182 0.4221% | $194,882.22 | 2 | 0 | |
| Svoronos Dawn | 50000 0.2393% | $110,500.00 | 2 | 0 | +2.84% | |
| Wachter Paul | director | 37161 0.1779% | $82,125.81 | 0 | 11 | |
| Hull Hans | SVP, Business Operations | 11320 0.0542% | $25,017.20 | 0 | 3 | |
| D'Souza Rupert | Chief Financial Officer | 10850 0.0519% | $23,978.50 | 1 | 0 | +0.06% |
| Beckman Richard | Chief Medical Officer | 10000 0.0479% | $22,100.00 | 1 | 0 | +0.6% |
| Bain Linda | Chief Financial Officer | 9000 0.0431% | $19,890.00 | 0 | 4 |
$12,784,645 | 193 | 20.49% | $40.32M | |
$77,062,892 | 41 | 13.96% | $46.48M | |
$6,787,959 | 35 | 49.84% | $49.84M | |
$459,011,221 | 33 | 33.04% | $43.91M | |
$167,476,357 | 20 | -1.54% | $50.04M | |
$47,863,113 | 17 | -22.07% | $41.99M | |
$20,234,041 | 17 | 2.09% | $39.66M | |
$7,733,516 | 17 | 73.42% | $48.52M | |
Adverum Biotechnologies, Inc. (ADVM) | $932,835 | 14 | -19.33% | $46.17M |
$1,044,754 | 13 | -23.07% | $45.3M | |
$31,978,951 | 10 | -70.03% | $45.77M | |
$232,423 | 8 | 14.22% | $43.52M | |
$22,090,972 | 7 | -3.49% | $38.93M | |
$106,599,960 | 6 | -7.63% | $47.07M | |
$43,326,461 | 6 | 16.01% | $47.77M | |
$1,801,761 | 4 | 54.67% | $48.86M | |
$105,079 | 4 | -41.57% | $46.01M | |
$32,000,000 | 3 | -41.00% | $48.15M | |
$157,740 | 3 | 153.95% | $48.14M |
| Increased Positions | 29 | +34.94% | 1M | +8.67% |
| Decreased Positions | 32 | -38.55% | 752,533 | -4.74% |
| New Positions | 11 | New | 326,868 | New |
| Sold Out Positions | 9 | Sold Out | 352,377 | Sold Out |
| Total Postitions | 80 | -3.61% | 16M | +3.93% |
| Bml Capital Management, Llc | $7,916.00 | 10.8% | 2.27M | 0 | 0% | 2024-12-31 |
| Tcg Crossover Management, Llc | $6,270.00 | 8.56% | 1.8M | -211,857 | -10.55% | 2024-12-31 |
| Franklin Resources Inc | $6,143.00 | 8.38% | 1.76M | 0 | 0% | 2024-12-31 |
| Principia Wealth Advisory, Llc | $5,922.00 | 8.08% | 1.7M | +366,155 | +27.52% | 2025-03-31 |
| Blackrock, Inc. | $4,980.00 | 6.8% | 1.43M | -58,427 | -3.93% | 2025-03-31 |
| Frazier Life Sciences Management, L.P. | $3,732.00 | 5.09% | 1.07M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $3,598.00 | 4.91% | 1.03M | +3,428 | +0.33% | 2024-12-31 |
| 5Am Venture Management, Llc | $1,890.00 | 2.58% | 541,666 | 0 | 0% | 2024-12-31 |
| Versant Venture Management, Llc | $1,769.00 | 2.41% | 506,821 | 0 | 0% | 2024-12-31 |
| Goldman Sachs Group Inc | $1,747.00 | 2.38% | 500,710 | +76,623 | +18.07% | 2024-12-31 |